polymerase in the process of PCR amplification, releasing the reporter dyes. Following PCR, plates were read using the 7900HT Fast Real-Time PCR system, and the data were analyzed using Allele Discrimination software (Applied Biosystems).
Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation Different mechanisms have been identified that protect acute myeloid leukemia (AML) cells against the cytotoxic actions of chemotherapy, including dysregulation of cellular cholesterol homeostasis. 1 So far, it has been shown that in vitro AML cells display an enhanced cholesterol metabolism. 2 Moreover, AML cells increase their cholesterol contents upon exposure to chemotherapeutic drugs, which may render them less Letters to the Editor susceptible to the cytotoxic actions of these drugs. 1 Therefore, interfering with the cholesterol metabolism by using statins to suppress cholesterol synthesis has been proposed as a method to improve antileukemic treatment strategies. 3 Statins (for example, simvastatin) are widely used plasma cholesterol-lowering drugs that inhibit cholesterol synthesis at the level of HMG-CoA reductase (HMG-CoAR) by blocking the conversion of HMG-CoA to mevalonate. Mevalonate is also the precursor of isoprenoids such as farnesyldiphosphate (FPP) and geranylgeranyldiphosphate (GGPP). Isoprenylation, catalyzed by farnesyltransferase or geranylgeranyltransferase, is required for the attachment of small GTPases (for example, Rho, Ras) to the plasma membrane and their subsequent participation in signal transduction pathways that regulate growth and survival. Statins induce cell death in various human AML cell lines, as well as in primary human AML cells in vitro.
1,4 Different mechanisms of action have been proposed for simvastatinmediated cell death, including the direct consequences of suppressed cholesterol synthesis and inhibition of isoprenylation and thereby the actions of signaling molecules such as Ras. 1, 5 Ras is frequently activated in AML cells by mutations, or because of the autocrine or paracrine production of growth factors. 6 We recently observed a heterogeneity in cytotoxicity among primary human AML cells upon in vitro treatment with simvastatin. 4 These results suggest that only a subset of AML patients may benefit from statin treatment. In order to be able to predict which patients may benefit from statin treatment, we investigated whether the differences in simvastatin-induced cytotoxicity are confined to differential effects on the cholesterol synthesis route or on the isoprenylation route.
To evaluate the cause of heterogeneity in simvastatin-induced cytotoxicity, we identified human AML cell lines with either a strong or a limited susceptibility to simvastatin-mediated cytotoxicity (Supplementary Figure S1 ). Based on an estimated half-maximal effective concentration (EC 50 ), we divided the cell lines into two groups: sensitive (EC 50 p5 mM; NB4, OCI-M3 and HL60) or insensitive (EC 50 X50 mM; UT7-GM, TF-1 and KG1a) to simvastatin. Mevalonate, the metabolite directly downstream of HMG-CoAR, was able to prevent simvastatin-induced cytotoxicity in all cell lines ( Figure 1 ). The effectivity of rescue varied from 36 to 100%, but was not significantly different (P ¼ 0.20) between sensitive and insensitive cell lines.
Statin-induced cytotoxicity has been attributed directly to the inhibition of cholesterol synthesis.
1,7 However, we found that squalene, a cholesterol precursor produced downstream of mevalonate, could not prevent simvastatin-induced cytotoxicity in AML cell lines (data not shown). In addition, ZGA, a squalene synthase inhibitor acting downstream of simvastatin in the cholesterol synthesis cascade, did not mimic the cytotoxic effects of simvastatin at concentrations reported to suppress de novo sterol synthesis 8 (data not shown). Therefore, inhibition of cholesterol production within the mevalonate pathway is unlikely to be responsible for the differences in simvastatininduced cytotoxicity in AML cells.
To assess whether the isoprenylation route is responsible for the heterogeneity in responsiveness, we determined if and to what extent two compounds involved in this route, that is, FPP and GGPP, are able to prevent simvastatin-induced cytotoxicity. Cytotoxicity could partially be prevented by FPP, and to a larger extent by GGPP (Figure 1) . The protective effects of FPP and GGPP were more pronounced in the sensitive cell lines compared with the insensitive ones, with an average rescue of 56 ± 27% versus 16 ± 15% for FPP (P ¼ 0.08) and 78 ± 29% versus 19±17% for GGPP (P ¼ 0.04).
To analyze whether simvastatin differentially affects protein isoprenylation, we determined the effects of simvastatin on isoprenylation of DnaJ (exclusively farnesylated) and Rap1 (exclusively geranylgeranylated). 9 The insensitive cell lines TF-1 and KG1a required a higher simvastatin concentration to achieve inhibition of farnesylation, and this inhibition was significantly less pronounced (Po0.04) than in the sensitive lines (Figure 2a, Supplementary Figure S2A ). Geranylgeranylation was blocked by simvastatin at very low concentrations in the sensitive cell lines (1 mM; P ¼ 0.002), whereas in the insensitive cell lines this inhibition was achieved only at a 10-fold higher simvastatin concentration (P ¼ 0.02; Figure 2a , Supplementary Figure S2B ). In addition, both tipifarnib, a specific inhibitor of farnesyltransferase, and GGTI-298, a specific inhibitor of geranylgeranyltransferase, had more pronounced cytotoxic effects in sensitive cells compared with the insensitive cell lines (Po0.05 at all tested concentrations, Figure 2b , and, for example, P ¼ 0.01 at 10 mM, Figure 2c , respectively). These data confirm that both the geranylgeranylation route and the farnesylation route are differentially affected 
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by simvastatin in sensitive and insensitive cell lines. Some reports suggest a role for protein geranylgeranylation, rather than for farnesylation, in statin-induced cytotoxicity in other (hematological) malignancies. 10 This is in part based on the observation that the geranylgeranyltransferase inhibitor GGTI-298 was less effective in inducing cytotoxicity than the farnesyltransferase inhibitor FTI-277 when used at comparable concentrations. 10 However, tipifarnib, the FTI used in the current study, was much more potent than GGTI-298 (Figures  2b and c) . In addition, we assessed the effect of simvastatin on isoprenylation of Ras. Again, inhibition of isoprenylation in sensitive cell lines was already significant at the lowest concentration (1 mM, P ¼ 0.03), whereas the insensitive cell lines showed inhibition only at higher concentrations, with significance achieved only at 100 mM (P ¼ 0.02; Figure 2a , Supplementary Figure S2C ).
Rho is exclusively geranylgeranylated, whereas Ras can be both geranylgeranylated and farnesylated. 9, 11 To dissect these separate processes, inhibitors of the Rho route and two distinct routes downstream of Ras were explored. Using the ROCK inhibitor Y27632 and the PI3K inhibitor LY294002, no differences in cytotoxic effects were observed between sensitive and insensitive cell lines (data not shown). However, the MEK inhibitor U0126 (downstream of Ras) increased cytotoxicity in a more pronounced manner in sensitive cell lines compared with insensitive ones (P ¼ 0.003; Figure 2d ). In addition, the insensitive cell lines required at least a 10-fold higher simvastatin concentration for the inhibition of ERK phosphorylation (450 mM) than the sensitive cell lines (5 mM) (Supplementary Figure S3A) . These data together indicate that mainly the Ras-MEK-ERK route is differentially affected by simvastatin in sensitive versus insensitive cell lines. The Ras transduction pathway is most likely not the only pathway involved in simvastatin-induced cytotoxicity because blocking the ERK activity with U0126, at a concentration that inhibited pERK expression but was not toxic to the cells, did not prevent statin-induced cytotoxicity in statin-sensitive cell lines (Supplementary Figure S3B ). Of course, several other proteins can become isoprenylated, for example, Rheb proteins, nuclear lamins, Rac and Cdc42. 12, 13 Finally, we investigated whether the observed findings also hold true for primary human AML cells. Heterogeneity in the cytotoxic effects of simvastatin, as well as differences in the degree of rescue by mevalonate, GGPP and FPP, were found in primary AML cells (Supplementary Table S1 ). Although more patients will have to be tested to allow valid conclusions, it is striking that the two samples in which pERK could not be detected were the least responsive to simvastatin (Supplementary Table S1 and Figure S4) . Also, the simvastatin concentration required for isoprenylation and pERK inhibition appeared to be generally lower in the sensitive samples, indicating that also in primary material the Ras-MEK-ERK route appears to be differentially affected by simvastatin.
In conclusion, the differential effects of simvastatin on AML cells can be assigned to differences in interference with the isoprenylation pathway rather than with cholesterol synthesis. Simvastatin-induced cytotoxicity resides, at least in part, in interference with Ras-MEK-ERK isoprenylation. Our findings can potentially be useful to identify AML patients who may benefit from simvastatin co-treatment.
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